Study study type PathologyT1T0Patientssample sizesROB Results

MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population

versus no additional treatment
atezolizumab alone
IMvigor-010, 2021
  NCT02450331
RCTMIBC - (neo)adjuvant (NA)atezolizumabobservationpatients aged 18 years or older and had histologically confirmed muscle-invasiveurothelial carcinoma of either the bladder or the upper tract as Adjuvant Therapy (Participants With High-Risk Muscle-Invasive Urothelial Carcinoma)406 / 403some concern
inconclusive
  • inconclusive 11 % decrease in events or deaths (EFS),events or deaths (EFS) (PE)
versus placebo
nivolumab alone
CheckMate 274 (all population), 2017
  NCT02632409
RCTMIBC - NA - all populationnivolumabplaceboadjuvant therapy patients with muscle-invasive high-risk urothelial carcinoma who had undergone radicalsurgery353 / 356low
conclusif
  • suggested 28 % decrease in RFS/DFS
  • demonstrated 30 % decrease in events or deaths (EFS) (PE)

MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive

versus placebo
nivolumab alone
CheckMate 274 (PDL1>1%), 2017
  NCT02632409
RCTMIBC - NA - PDL1 positivenivolumabplaceboadjuvant therapy patients with muscle-invasive high-risk urothelial carcinoma who had undergone radicalsurgery140 / 142low
conclusif
  • suggested 45 % decrease in RFS/DFS
  • demonstrated 45 % decrease in events or deaths (EFS) (PE)